Coronavirus

Surrozen Reports Second Quarter 2022 Financial Results

Phase 1 clinical trials of SZN-1326 and SZN-043 initiated and ongoingPreclinical proof-of-concept data for multiple programs presented and published in…

3 years ago

Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2022

Menlo Park, California, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today…

3 years ago

CorMedix Inc. Reports Second Quarter and Six Month 2022 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc.…

3 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data…

3 years ago

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing…

3 years ago

imaware and Elo Health Collaborate to Scale Personalized Nutrition for Patients

imaware’s customizable at-home diagnostics solutions enables Elo to reach more patients and engage them earlier on in their health journeyAUSTIN,…

3 years ago

TOMI Environmental’s SteraMist Provides Protection Against Monkeypox and Other Pathogens As World Combats Increasing Frequency of Outbreaks

Coronavirus Is Not An Outlier In Interconnected Age of Air Travel and Urbanization; TOMI Environmental Partners With Customers To Provide…

3 years ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

-CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, with the European Medicines…

3 years ago

Vaxart Appoints W. Mark Watson to its Board of Directors

Non-executive director to bring extensive life science industry and finance experience SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE)…

3 years ago

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has…

3 years ago